Professor Mok Shu Kam Tony
Chairman,
Department of Clinical Oncology,
The Chinese University of Hong Kong
STUDY DESIGN
The ALEX study established alectinib as the first-line treatment for advanced anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC).1 Earlier analyses demonstrated progression-free survival (PFS) adv
November 20, 2025
